Washington, USA
+919405476170
+919405476170

Wholesale Tecentriq 1200 mg for US Clinics | Ernest Oncology India Supply

Tecentriq 1200 mg Injection: Advanced PD-L1 Blockade for Precision Immunotherapy



Are you seeking a trusted Tecentriq 1200 mg injection exporter from IndiaErnest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a leading global supplier and bulk distributor of innovative oncology immunotherapies. We maintain a high-authority, cold-chain-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving biologics reach oncology centers with maximum integrity and efficient global logistics.





Detailed Product Overview: What is Tecentriq 1200 mg?


Tecentriq 1200 mg Injection (Atezolizumab) is a breakthrough humanized monoclonal antibody designed for targeted cancer immunotherapy. It represents a significant advancement in the field of checkpoint inhibitors, specifically targeting the PD-L1 pathway to reactivate the body's immune response against malignant cells.

Manufactured by Roche/Genentech, Tecentriq 1200 mg is a specialized 20 mL vial used in hospitals and specialty clinics worldwide. For international B2B procurement, Tecentriq offers a clinically proven solution for some of the most aggressive and difficult-to-treat cancers, providing a powerful alternative to traditional chemotherapy.

Primary Therapeutic Indications


Tecentriq 1200 mg is FDA and EMA approved for several critical indications:

  1. Non-Small Cell Lung Cancer (NSCLC): Used as a first-line therapy for metastatic NSCLC (high PD-L1 expression) and as an adjuvant treatment for early-stage NSCLC following surgery and chemotherapy.

  2. Small Cell Lung Cancer (SCLC): Indicated as a first-line treatment for extensive-stage SCLC in combination with carboplatin and etoposide.

  3. Hepatocellular Carcinoma (HCC): Used in combination with bevacizumab for patients with unresectable or metastatic liver cancer.

  4. Urothelial Carcinoma: For patients with advanced bladder or urinary tract cancer who are ineligible for cisplatin chemotherapy.

  5. Triple-Negative Breast Cancer (TNBC): In combination with nab-paclitaxel for PD-L1-positive, metastatic TNBC.




Mechanism of Action: How Tecentriq Works


Tecentriq operates by "unmasking" cancer cells that attempt to hide from the immune system:

  • Targeting PD-L1: Many cancer cells express a protein called PD-L1 (Programmed Death-Ligand 1), which binds to PD-1 and B7.1 receptors on T-cells to deactivate them.

  • Checkpoint Blockade: Tecentriq binds directly to PD-L1, blocking these inhibitory interactions.

  • Immune Reactivation: By neutralizing the "cloaking" effect of PD-L1, Tecentriq restores the T-cells' ability to recognize and attack the tumor, effectively utilizing the patient's own immune system to combat the disease.




Administration and Safety Guidelines

  • Dosage: Typically administered as an intravenous (IV) infusion of 1200 mg every three weeks.

  • Infusion Duration: The initial infusion is usually given over 60 minutes. If well-tolerated, subsequent infusions can be shortened to 30 minutes.

  • Storage: Must be stored under strict cold-chain conditions (2°C to 8°C / 36°F to 46°F). Do not freeze or shake.

  • Key Precautions:

    • Immune-Mediated Adverse Reactions: Monitor for signs of pneumonitis, hepatitis, colitis, and endocrinopathies (thyroid/adrenal issues).

    • Infusion-Related Reactions: Patients should be observed for fever, chills, or shortness of breath during administration.

    • Fertility & Pregnancy: Advise patients of reproductive potential & the risks to a fetus.




Why Source Tecentriq from Ernest Oncology?

  • Authentic Indian Exporter: Direct access to genuine Roche/Genentech inventory, ensuring 100% product authenticity and competitive wholesale pricing.

  • Cold-Chain Excellence: Validated temperature-controlled shipping to preserve the delicate protein structure of Atezolizumab during transit to the USA, UK, Australia, and South Africa.

  • Global Logistics Authority: Expertise in managing international customs and regulatory documentation for specialty biologics.

  • Bulk Supply Stability: We specialize in large-scale procurement for government tenders, private hospitals, and regional medical distributors.



📞 Contact Ernest Oncology — Pharmaceutical Exporter from India


[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]

🌐 Websites:

📧 Email: exports@ernestpharmaceuticals.com

📦 Business Type: Exporter | Bulk Supplier | Distributor  

📲 WhatsApp: +91 93599 02383

 🔗 Direct Link: Chat on WhatsApp

 2026-04-15T11:50:17

Keywords